CoChat

The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings

Open access
Mallat, A, Teixeira‐Clerc, F, Deveaux, V, Manin, S, Lotersztajn, S · 2011 · British Journal of Pharmacology
Cited by 131

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Chronic liver diseases represent a major health problem due to cirrhosis and its complications. During the last decade, endocannabinoids and their receptors have emerged as major regulators of several pathophysiological aspects associated with chronic liver disease progression. Hence, hepatic cannabinoid receptor 2 (CB 2) receptors display beneficial effects on alcoholic fatty liver, hepatic inflammation, liver injury, regeneration and fibrosis. Cannabinoid receptor 1 (CB 1) receptors have been implicated in the pathogenesis of several lesions such as alcoholic and metabolic steatosis, liver fibrogenesis, or circulatory failure associated with cirrhosis. Although the development of CB 1 antagonists has recently been suspended due to the high incidence of central side effects, preliminary preclinical data obtained with peripherally restricted CB 1 antagonists give real hopes in the development of active CB 1 molecules devoid of central adverse effects. CB 2‐selective molecules may also offer novel perspectives for the treatment of liver diseases, and their clinical development is clearly awaited. Whether combined treatment with a peripherally restricted CB 1 antagonist and a CB 2 agonist might result in an increased therapeutic potential will warrant further investigation. LINKED ARTICLES This article is part of a themed issue on Cannabinoids in Biology and Medicine. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐7

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01397.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 131

Metadata

Authors
Mallat, A., Teixeira‐Clerc, F., Deveaux, V, Manin, S., & Lotersztajn, S.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2011-07-12
Volume
163
Issue
7
Pages
1432-1440
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1510152729
Cited by
131
References
10
FWCI
6.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01397.x
The paper
Mallat, A., Teixeira‐Clerc, F., Deveaux, V, Manin, S., & Lotersztajn, S. (2011). The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01397.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.